We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Therapies indicated for HF like finerenone should be continued long term without interruption or premature discontinuation. Long-term use of these therapies, as recommended in clinical practice guidelines, is expected to maximize cardiovascular protection.”
“These data bolster current guidelines on the need for maintenance of HF medical therapies to maximize long-term treatment gains, even in a clinically stable individual and even in the setting of HFpEF.”
“This analysis offers a rare glimpse into what happens when patients stop taking an MRA.”
No takes yet. Share an insight, caveat, or question.
Ahmed B Shamsulddin (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: